{"title": "Influence of vitamin D supplementation on SARS-CoV-2 vaccine efficacy and immunogenicity (preprint)", "author": "David A Jolliffe; Giulia Vivaldi; Emma S Chambers; Weigang Cai; Wenhao Li; Sian E Faustini; Joseph M Gibbons; Corinna Pade; Alex Richter; Aine McKnight; Adrian R Martineau", "url": null, "hostname": null, "description": null, "sitename": "Influence of vitamin D supplementation on SARS-CoV-2 vaccine efficacy and immunogenicity (preprint) | medrxiv; 2022.", "date": "2022-07-15", "cleaned_text": "[Vitamin D deficiency]has been reported to associate with impaired development of [antigen]-specific responses following [vaccination]. We aimed to determine whether might and [efficacy]of sub-studies nested within the CORONAVIT randomised controlled trial, which investigated effects of offering [vitamin D]supplements at a [dose]of 800 or 3200 IU per day vs. no offer on [risk]of acute [respiratory infections], including COVID-19, in UK [adults]with circulating 25-hydroxyvitamin D concentrations under 75 nmol/L. Sub-study 1 investigated effects of [vitamin D]supplementation on [risk]of breakthrough SARS-CoV-2 infection following two doses of SARS-CoV-2 vaccine. Sub-study 2 (n=1853) investigated effects investigated effects of [vitamin neutralising antibody and after [SARS-CoV-2] [vaccination]. Results:1945/2823 two doses of [ChAdOx1 nCoV-19](Oxford AstraZeneca); the remainder received two doses of [BNT162b2](Pfizer). [Vitamin D]supplementation did not influence [risk]of breakthrough SARS-CoV-2 infection (800 IU per day vs. no offer adjusted [hazard]ratio 1.28, 95% CI 0.89 to 1.84; 3200 IU per day vs. no offer 1.17, 0.81 to 1.70). Neither did it influence IgGAM anti-Spike titres, antibody 800 or 3200 IU per day did not "}